Cited 12 times in
A prospective randomized trails comparing intravenous 5 fluorouracil and oral doxifluridine as postoperative adjuvant treatment for advanced rectal cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김남규 | - |
dc.date.accessioned | 2019-11-11T05:01:11Z | - |
dc.date.available | 2019-11-11T05:01:11Z | - |
dc.date.issued | 2000 | - |
dc.identifier.issn | 1068-9265 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/171545 | - |
dc.description.abstract | Background: Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate. Intravenous 5-fluorouracil (5-FU) and leucovorin has been a mainstay of chemotherapy, but oral 5-FU derivatives have been shown a comparable antitumor activity. Intravenous 5-FU and oral doxifluridine were compared with respect to therapeutic efficacy, drug toxicity, and quality of life. Methods: A total of 166 patients were randomized to receive intravenous 5-FU (450mg/m2/day) or oral doxifluridine (900mg/m2/day) in combination with leucovorin (20mg/m2/day) for depth of invasion, nodal status, metastasis (TNM) stage II and III patients between October 1997 and February 1999. Consecutive daily intravenous infusion for 5 days per every month for a total of 12 cycles (IV arm, n 5 74) and oral doxifluridine daily for 3 weeks and 1 week rest for a total of 12 cycles (oral arm, n 5 92). Drug toxicity and quality of life were observed. Quality of life was scored according to 22 daily activity items (good, $ 71; fair, , 70; poor, , 52). Results: There was no difference of sex between two groups (IV arm: male/female 5 45/29, oral arm: male/female 5 59/33). The mean age was 52.3 vs. 59.5, respectively. There was also no difference of TNM stage distribution and type of operation between groups (P . .05). Mean numbers of chemotherapy cycles were 6.5 6 3.7 (IV arm) vs. 7.2 6 4.3 (oral arm), respectively. The rate of recurrence was 9/74 (12.1%) in the IV arm and 6/92 (6.5%) in the oral arm, respectively (P 5 .937). Local recurrence was 2/74 (stage III; 2.7%) in the IV arm and 1/92 (stage II;1.1%) in the oral arm, respectively. Systemic recurrence was 7/74 (stage III; 9.4%) in the IV arm and 5/92 (stage III; 5.4%) in the oral arm, respectively. The most common site of systemic recurrence was the liver. Toxicity profile was as follows: leukopenia (30/74 vs. 17/92) and alopecia (21/74 vs. 13/92) were statistically more common in the IV arm. Diarrhea was more common in the oral arm. Poor quality of life score between two groups was observed at 1 month (23.9% vs. 13%) and 2 months (15.8% vs. 3.7%) after chemotherapy. Good quality of life score was observed at 1 month (19.5% vs. 49%) and 2 months (47% vs. 72%), respectively (P , .05). Conclusions: Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy. The oral regimen also can be safely given with appropriate toxicity and tolerability. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | Annals of Surgical Oncology | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adenocarcinoma/drug therapy* | - |
dc.subject.MESH | Adenocarcinoma/mortality | - |
dc.subject.MESH | Adenocarcinoma/pathology | - |
dc.subject.MESH | Adenocarcinoma/surgery | - |
dc.subject.MESH | Administration, Oral | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/administration & dosage* | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Floxuridine/administration & dosage* | - |
dc.subject.MESH | Fluorouracil/administration & dosage* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infusions, Intravenous | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.subject.MESH | Postoperative Period | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Quality of Life | - |
dc.subject.MESH | Rectal Neoplasms/drug therapy* | - |
dc.subject.MESH | Rectal Neoplasms/mortality | - |
dc.subject.MESH | Rectal Neoplasms/pathology | - |
dc.subject.MESH | Rectal Neoplasms/surgery | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | A prospective randomized trails comparing intravenous 5 fluorouracil and oral doxifluridine as postoperative adjuvant treatment for advanced rectal cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Jin Sik Min | - |
dc.contributor.googleauthor | Nam Kyu Kim | - |
dc.contributor.googleauthor | Jea Kun Park | - |
dc.contributor.googleauthor | Seong Hyun Yun | - |
dc.contributor.googleauthor | Jae Kyung Noh | - |
dc.identifier.doi | 10.1007/s10434-000-0674-9 | - |
dc.contributor.localId | A00353 | - |
dc.relation.journalcode | J00179 | - |
dc.identifier.eissn | 1534-4681 | - |
dc.identifier.pmid | 11034245 | - |
dc.identifier.url | https://link.springer.com/content/pdf/10.1007%2Fs10434-000-0674-9.pdf | - |
dc.subject.keyword | Rectal cancer | - |
dc.subject.keyword | Postoperative adjuvant | - |
dc.subject.keyword | 5-Fluorouracil | - |
dc.subject.keyword | Doxifluridine | - |
dc.contributor.alternativeName | Kim, Nam Kyu | - |
dc.contributor.affiliatedAuthor | 김남규 | - |
dc.citation.volume | 7 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 674 | - |
dc.citation.endPage | 679 | - |
dc.identifier.bibliographicCitation | Annals of Surgical Oncology, Vol.7(9) : 674-679, 2000 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.